King's College London

Research portal

British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis

Research output: Contribution to journalReview article

Nick Powell, Hajir Ibraheim, Tim Raine, Richard A. Speight, Sophie Papa, Oliver Brain, Michael Green, Mark A. Samaan, Lavinia Spain, Nadia Yousaf, Nikki Hunter, Lucy Eldridge, Polychronis Pavlidis, Peter Irving, Bu'Hussain H. Hayee, Samra Turajlic, James Larkin, James O. Lindsay, Martin Gore

Original languageEnglish
Pages (from-to)679-697
Number of pages19
JournalThe Lancet Gastroenterology and Hepatology
Volume5
Issue number7
DOIs
PublishedJul 2020

King's Authors

Abstract

Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction. Diarrhoea and gastrointestinal tract inflammation are common and sometimes serious side-effects of this type of therapy. Prompt recognition of gastrointestinal toxicity and, in many cases, rapid institution of anti-inflammatory or biologic therapy (or both) is required to reverse these complications. Management of organ-specific complications benefits from multidisciplinary input, including engagement with gastroenterologists for optimal management of immune checkpoint inhibitor-induced enterocolitis. In this British Society of Gastroenterology endorsed guidance document, we have developed a consensus framework for the investigation and management of immune checkpoint inhibitor-induced enterocolitis.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454